People in the pharmaceutical world have spent decades seeking ways to keep eye inflammation under control. Glucocorticoids set a new standard as corticosteroids became a core part of medical practice. Fluorometholone Acetate sprouted from years of effort to tweak older steroids for better effect and fewer side effects. Researchers in the mid-20th century figured out how to attach fluorine atoms to the base steroid structures, chasing higher potency and better safety. As patents expired on predecessor molecules, makers shifted focus to creative chemical tricks like esterification, which shaped the distinct properties of the acetate version versus plain fluorometholone. It didn't happen by accident. This process took persistence from med chemists exploring structure-activity relationships, plus real-world feedback from eye doctors who watched patients every day. Regulatory standards grew stiffer as more data poured in, pushing buyers and researchers alike to demand details about safety, especially as worries about cataracts and raised eye pressure mounted from long-term steroid use.
Fluorometholone Acetate makes up the cornerstone of treatment for many types of non-infectious eye inflammation. Compared to its relatives, it has earned trust because it reduces swelling well without stoking eye pressure as much as some older steroids. Its acetate ester means it lingers longer at the eye’s surface, letting drops work harder between uses. Compounding pharmacies and big-name manufacturers sell it as suspensions, most often at 0.1% or 0.25% strength. Out on the market, you’ll spot it under names like Flarex and Florate. While some other forms like ointments serve special needs, drops remain the standard for easy dosing and broad use.
This compound carries the chemical formula C24H31FO6. The fluorine atom at the ninth position on the steroid nucleus stands front and center for enhancing anti-inflammatory activity. The molecular mass clocks in around 434.5 g/mol. As a white to off-white powder, it grips only lightly to water—solubility runs low—so suspending agents and surfactants need careful blending during preparation. It's sensitive to light and shifts color if poorly stored, making it important to pack it in amber bottles. Pharmaceutical standards call for pH adjustment since the active molecule breaks down quickly in environments that drift too acidic or alkaline.
Labs test each lot for purity, generally requiring a minimum of 98% active content with tight controls against related impurities. In specs from the United States Pharmacopeia, loss on drying must be low—usually under 1%—and residual solvents must not exceed thresholds laid out by the International Conference on Harmonisation (ICH). Pharmacies label products with clear batch numbers, concentration details, storage instructions—usually between 2-25°C and protected from light—and annotated expiration dates. The push for transparency led regulators to insist that labeling spell out possible interactions, shelf life, and recommended frequency.
Making Fluorometholone Acetate starts with raw fluorinated corticosteroid, synthesized through the fluorination of progesterone-like bases using Selectfluor or similar reagents under controlled conditions. The acetate group gets tacked on through esterification with acetic anhydride, employing gentle heat and a suitable acid catalyst. The product goes through repeated purification, often with recrystallization in alcohols or filtration using activated charcoal. After confirming structure and purity, processors micronize the powder to optimize eye penetration, blend it with sterile suspending vehicles, and bottle it by aseptic techniques. Running sterile filtration, in-process endotoxin checks, and particulate testing under cleanroom standards stays non-negotiable because of direct human use.
On a chemical level, the introduction of fluorine and an acetate group tailors both bioactivity and solubility. Removing the acetate group by hydrolysis reverts it back to the alcohol form, which shifts the duration of action when inside the eye. The steroid ring is sturdy but stands vulnerable to acid or base hydrolysis under careless storage. Research groups often try new modifications—substituting halogens, lengthening ester chains, altering side-chain oxidation patterns—to hunt for greater anti-inflammatory effect with less risk of steroid-induced glaucoma or cataract. Attempts to further boost its selectivity mostly spin off into development of “soft” steroids, which break down faster after hitting their target site.
Fluorometholone Acetate can show up in records and bottles under several names, depending on region and manufacturer. Besides the generic, physicians and pharmacists know it as Flarex, Florate, and sometimes FML-Acetate. Scientific literature may reference it by its systematic name, (6α,11β)-9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione 17-acetate. International health agencies often stick to its INN (International Nonproprietary Name) for consistent tracking across borders.
Lab workers prepare fluorinated corticosteroids under fume hoods to cut down on accidental inhalation. Since the raw materials break down or react under heat and humidity, standard operating procedures call for temperature and moisture controls from start to finish. PPE—gloves, masks, goggles—remains essential for those involved in scale-up and purification. In clinical use, regulators approve only GMP-certified batches, and doctors monitor patients for signs of increased intraocular pressure, infection, and delayed wound healing, hallmarks of corticosteroid complications. Health agencies, including the US FDA and EMA, require postmarket surveillance, pushing companies to track side effects and adverse events over years.
In clinics, ophthalmologists hand out Fluorometholone Acetate drops for a wide range of problems—post-surgical inflammation, allergic conjunctivitis, and chronic uveitis among them. It targets the eye to keep down swelling and pain after cataract extraction, LASIK, or trauma. People facing allergy season often benefit when other treatments fall short. Careful dosing protocols help keep patients safe, as doctors stagger use to avoid prolonged exposure. New interest has emerged outside strict ophthalmology, such as in clinical studies looking at its potential on the skin (cutaneous conditions) and experimental uses in veterinary medicine. Still, the main audience remains patients with acute or chronic non-infectious eye inflammation.
Academic labs often explore alternatives for controlling ocular inflammation that pose less risk than conventional steroids. Studies catalogue structure-activity relationships as they seek tweaks yielding better disease control or fewer side effects. Drug companies invest in new formulations, including sustained-release microspheres and nanoparticle suspensions, to improve delivery and reduce dose frequency. Calls for greener synthesis methods echo across the industry, as environmental agencies squeeze down on waste from halogenated intermediates and organic solvents. Ongoing field trials compare newer analogs against Fluorometholone Acetate to find out if gains in efficacy justify the higher costs.
Toxicologists continue to monitor this drug’s risks, especially since long-term exposure to corticosteroids can trigger tissue thinning, higher intraocular pressure, and opportunistic infections. Eye clinics routinely test patients for steroid response, because some people react with dangerous spikes in intraocular pressure, leading to irreversible vision loss. Animal studies point to dose-dependent cataract formation and stunted wound healing, with recovery tied directly to duration and intensity of dosing. The sharp eye on toxicity trails back to lessons from early glucocorticoids, which caused more harm than good when safety checks lagged behind marketing. Makers must present years of real-world and lab data before regulators sign off on updates or new market pushes.
Researchers aim to further minimize downsides by blending precision medicine with classic pharmacology. Personalized dosing schedules based on patient genetics may cut risk for steroid response. New delivery vehicles continue to attract startup investment, from cyclodextrin-based drops to thin film inserts that stick to the eye for slow release. Interest in biosimilars highlights a growing trend toward making this powerful tool available at a better price point for developing markets. Calls to replace halogenated starting materials with greener options underscore the pressure to curb chemical waste. Scientific focus sharpens not only on the drug’s direct effect but its role as part of a combined strategy with anti-allergy or immune modulating agents. Patients, pharmacists, and regulators all watch closely as fresh data rolls out, shaping the next set of safety guidelines and clinical protocols. If the history of steroid drugs keeps teaching anything, the biggest advances come from listening—to patient experience, molecular tweaks, and the accumulating wisdom of decades-long surveillance.
Fluorometholone acetate often comes up in conversations around eye drops and ointments prescribed after eye surgery or to help calm inflammation. It's a corticosteroid, which means it works by lowering the body’s natural swelling and irritation response. After years of shuffling through prescriptions and talking to eye doctors, I've seen this medication offered to folks struggling with redness, itch, or swelling in their eyes, especially after procedures like LASIK or cataract extraction.
Plenty of people rely on it for relief when allergy seasons hit hard, or when their eyes get irritated after coming in contact with dust or contact lenses. Doctors also reach for it when other steroid drops fall short. It isn’t for everyone–some medical conditions like certain viral eye infections make steroid drops risky. So it’s critical for people to check in with their doctor before grabbing a bottle from the pharmacy.
Inflammation in and around the eye can quickly spiral. One day it’s just mild swelling, and soon enough you’re squinting in pain, and your vision goes fuzzy. Out of all the corticosteroids I’ve seen prescribed for the eyes, fluorometholone acetate stands out because it creates less pressure inside the eye compared to some other steroids like prednisolone. That’s important, especially for people who have a family history of glaucoma or have already noticed pressure creeping up during regular eye exams.
The medication allows eye specialists to reduce inflammation without risking harmful side effects as often as might happen with stronger steroids. At low doses, side effects rarely show up. Still, careful tracking matters. My own relatives who have used steroid drops learned to keep those follow-up appointments because ignoring high eye pressure can lead to bigger trouble, including vision loss.
I’ve noticed some clinics shy away from routine use of fluorometholone acetate unless symptoms push in that direction. In part, it comes down to cost and insurance coverage. Generic versions exist, but some plans ask patients to try cheaper, older medications first. That can feel frustrating when you just want the irritation to stop.
One important point: overusing any corticosteroid eye drop, including fluorometholone acetate, can open the door to eye infections or mask early signs that something else is wrong. The solution? Always check back with a physician. An honest talk about risks, and watching for any changes in vision or unusual pain, helps catch problems early.
Looking at the bigger picture, technology has begun to change how we use these medications. Automated reminders, home monitoring devices, and click-to-send questions for the doctor all help people stay on track with their dosing. Reading through patient forums, it’s clear that folks value access to transparent information–getting the facts about benefits alongside real warnings about misuse.
Pharmacies, too, can step up by flagging high-risk prescriptions. Many pharmacists will gently remind patients to watch for pressure buildup or infection signs. Partnerships between pharmacists, vision specialists, and patients will shape better safety and more positive experiences with medications like fluorometholone acetate. It all comes down to making sure that anyone using these drops gets the relief they want, without stumbling into complications they never saw coming.
I remember my first experience working at a community pharmacy when an older woman struggled with persistent eye inflammation. Her doctor handed her a prescription for Fluorometholone Acetate—a corticosteroid that helps temper the body’s immune response. Unlike antibiotics, this medication zeroes in on redness, swelling, and soreness instead of infection. People rely on this option for various eye problems, but getting the most benefit from it means knowing how to use it properly.
Ophthalmic drops land among the trickier medicines to apply. Most patients feel uncertain about how many drops to use, where to look, or if touching the bottle to the eye matters. I’ve watched folks squeeze out far too much, wasting medicine or flooding their cheeks. That’s where clear instructions come in—it’s about keeping things simple and safe. Before anything else, handwashing removes stubborn bacteria and dirt. Any germs lingering on the hands could head straight for the eye during application.
Next comes shaking the bottle, especially if the label recommends it. The active ingredient can settle at the base, and skipping this step leaves uncertain dosing. After that, tilting the head back helps. I’ve found looking up at the ceiling gives the steadiest target. Pull the lower eyelid down and create a pocket for the drop. One drop usually brings enough medicine—extra drops don’t boost effects but could raise risks. Try not to blink or squeeze the eyelid too tightly after putting the drop in, or the dose may flush out. Count to thirty with eyes closed for best results. Pressing gently on the corner of the eye helps slow drainage into the nose, which may reduce side effects.
Fluorometholone Acetate does not act like a casual painkiller. Overuse raises chances for trouble, like cataracts or raised eye pressure. Missing doses, on the other hand, creates gaps in protection. Patients shouldn’t stop suddenly either, especially if they’ve used the drops for many weeks. Tapering lets the body adapt. Many times, folks stash drops wherever is handy. Yet sunlight, bathroom heat, or fridge cold can change the medicine. Most bottles work best at room temperature, screwed shut to keep out bacteria. Toss any bottle after the date on the label passes, and never share eye drops—cross-contamination spreads infections rapidly.
Regular check-ins with an eye specialist often make a difference in catching hidden problems. Vision tests and pressure checks let doctors spot early warning signs. Some people, like those who wear contact lenses, need extra advice. Soft lenses absorb the medicine, trapping it against the eye. Always ask about wait times before putting lenses back in—usually about fifteen minutes after applying the drop.
Many clients I’ve assisted felt uncertain at first, but their confidence grew with simple routines and honest conversations. Asking questions counts for more than memorizing instructions. If side effects pop up—eye pain, blurred vision, rainbow halos, or sudden swelling—patients should reach out fast. Delaying could invite lasting harm. Quality care starts with careful use, a little patience, and trust between patient and professional.
Fluorometholone acetate sits on pharmacy shelves as a common corticosteroid eye drop meant to reduce inflammation and irritation. Eye doctors reach for it when folks have red, itchy, or swollen eyes from allergies, injury, or certain surgeries. Plenty of people use this medication safely, but side effects do pop up and deserve a practical look.
Eye drops never seem pleasant. Fluorometholone acetate often causes a temporary stinging or burning feeling right after the drops hit the eye. Sometimes, the drops trigger blurred vision for a short time or leave a strange taste in the mouth. Using these types of drops, a few people report redness, watery eyes, or a gritty sensation like sand stuck under the eyelid.
Many folks start out dismissing these sorts of issues as normal, but problems can build. Having worked in a pharmacy and witnessed plenty of patients, I’ve seen people rush back nervous about changes in their vision or ongoing discomfort. These mild side effects often fade as your eye adjusts, yet always signal to keep a close watch.
Fluorometholone acetate brings serious risks, which rise if folks keep using the drops for weeks. Corticosteroids can increase pressure inside the eye. Scientists and clinicians call this intraocular pressure, which sometimes leads to glaucoma. Glaucoma slowly damages the optic nerve and steals vision, usually unnoticed at first. Some people become more sensitive to this pressure, especially those with a family history of eye disease or older adults. I remember an older patient, content one week and then suddenly worried—her regular pressure checks caught a dangerous spike just in time.
Another risk involves cataracts. Steroid eye drops cause cataracts in some people over months or years, clouding up vision and making bright days unbearable. Fungal or bacterial infections become easier to catch because the drug calms the immune response inside the eye. I’ve heard stories from eye doctors about infections developing silently since redness and pain get disguised by the steroid. Infection can threaten eyesight in serious cases if people don’t seek quick treatment.
Side effects are no joke, and personal vigilance helps more than anything. Eye pressure checks protect against glaucoma—nearly every patient using steroid drops should expect these routine visits. Following prescriptions exactly matters, since overuse lifts risks. Doctors often give the lowest effective dose for the shortest time possible to reduce trouble. Most pharmacies give written warnings about possible complications, yet the words can blend in with other papers.
If someone notices pain, changes in vision, halos, or increased sensitivity to light, the best move means calling the doctor, not waiting until the next scheduled visit. Patients using contact lenses need to talk with their eye doctor because the drops can cause lens discoloration or trap bacteria. Washing hands before every use and keeping the bottle tip away from the eye also helps cut infection risks.
Fluorometholone acetate can treat tough eye problems, but it deserves the same respect as any other prescription with important side effects. Patients who learn about risks, attend regular checkups, and speak up about odd symptoms have the best chance at finishing treatment with healthy vision intact. Trust your instincts—if something feels off, reaching out for advice just might protect your sight.
Fluorometholone acetate, usually prescribed as an eye drop, steps in to calm inflammatory eye conditions. For years, steroid drops like this have brought relief for red, swollen eyes after surgery or during flare-ups. What matters most isn’t whether it works in the short run—most people see relief—but what happens when weeks turn into months and the bottle still sits on your bathroom shelf.
Steroid eye drops, even the ones considered “mild” by doctors, don’t play nice with eyes forever. One big concern from long-term users involves an increase in intraocular pressure—the core driver behind glaucoma. I watched a neighbor’s dad struggle with vision problems after his pressure crept up for years from extended steroid use. He never felt a thing until the doctor noticed damage during a check-up. A review published in Current Opinion in Ophthalmology points out that steroid-induced glaucoma can sneak up, especially if regular monitoring gets skipped.
Fluorometholone acetate has a reputation for causing less of a spike than heavier steroids. Still, even at a lower risk level, eyes aren’t immune forever. Children, people with a family history of glaucoma, or anyone using these drops for months—especially without physician oversight—face more risk. Data shows about 5-6% of adults experience pressure rises, but kids are even more sensitive. Long-term use can also thin the cornea, delay healing, or stir up secondary infections. The eye’s defenses take a hit, opening the door for bacteria or viruses hiding in the shadows.
Anyone considering these drops for more than a week should get a clear, honest plan from their eye doctor. This means more than just a one-time exam. It means regular pressure checks and a conversation about family history. For anyone with previous steroid response or eye pressure problems, alternatives for long-term inflammation, like cyclosporine or lifitegrast, might fit better. These tend to carry fewer pressure-related side effects.
It’s not about avoiding steroids altogether. They offer real relief that changes lives, especially after surgery or during sudden inflammatory attacks. Short courses under watchful eyes bring quick results with small risk. Problems start when bottles linger in purses and glove compartments. Patients stretch out refills or self-medicate minor irritations long past the original injury or illness. I’ve seen friends brush off “just a little blur” or “mild halos at night,” not knowing those signs can lead to permanent changes if ignored.
Conversations between doctors and patients make the biggest difference with steroids like fluorometholone acetate. Sharing changes in vision, coming in for routine checks, and using drops exactly as prescribed help balance relief with safety. Tech has improved how quickly eye pressure problems get spotted, but not everyone gets routine follow-up without reminders.
Medical advances haven’t replaced the basic truth that any steroid drop, even the mildest, needs respect over time. Far too many people learn this lesson after eyesight suffers. Safety comes from education and a plan, not from trusting “mild” means harmless.
Fluorometholone acetate often appears in eye drops for inflammation after surgery or injury. For many people, it feels like a miracle fix for eye redness or swelling. Still, not everyone walks the same path, especially those who are pregnant or breastfeeding. The body acts differently during these times, and new medicine often brings more questions than answers.
During pregnancy, everything put into or onto the body runs through a filter of caution. Bodies change, hormones shift, and the baby drinks in more than just food. Using fluorometholone acetate means adding a steroid into the mix. Because these steroid eye drops absorb a little through the eyes, some ends up in the bloodstream. Drug makers haven’t run enough careful studies on pregnant people, at least not the kind that set health professionals at ease. Animal research turned up some red flags, including birth defects from corticosteroids when given in high doses. Scientists can’t just copy animal results over to people, but it raises concern all the same.
Most doctors suggest looking at other ways to treat eye inflammation when pregnancy is on the table. If there’s no option, then close monitoring steps in. The stakes run higher in the first three months, the window where tiny organs form and risk looms largest.
Breastfeeding mothers have plenty to juggle already. Adding corticosteroid eye drops into daily life brings its own question: does the drug reach breast milk, and what does that do for the baby? Most medicines given as eye drops reach the body in tiny amounts. Still, tiny amounts can sometimes travel far. There’s little research showing exactly how much passes into milk or if that amount can bother a newborn. Long-term steroid use, even at low doses, links with slowed growth in infants in rare cases. For babies born early or dealing with health issues, doctors get extra careful about exposures.
Most eye doctors and pediatricians turn to non-steroid treatments or stick to mild products for new mothers. Eye compresses, artificial tears, and checking for allergies may solve the problem without steering into risky territory. If inflammation refuses to budge and eye health faces bigger threats, then steroid drops may get used for a few days, but only after talking out risks and benefits.
Trust builds in the things we talk through. Anyone who faces eye inflammation during pregnancy or breastfeeding should hear the facts straight from a medical professional, not just from someone else’s story. During years working in healthcare and writing about drug safety, I have seen how much honesty matters. The doctor checks the patient’s overall health and asks about allergies, other medications, and the baby’s medical picture. No decision happens in a vacuum. The patient shares worries, and together with the doctor, picks the safest route. Evidence might run thin, but a conversation based on real risk, not just fear, puts everyone on steadier ground.
Weighing the benefits and risks sounds simple, but in real life, decisions get heavy. A healthy baby and a healthy parent matter equally. Checking resources by the FDA or trusted medical websites can help clarify confusing advice online. Keeping communication open with care providers and not hiding symptoms or skipped doses builds safer outcomes for parent and child alike. Medicine asks us to look out for each other with facts, honesty, and care. That’s how the safest choices get made, even when information is limited.
| Names | |
| Preferred IUPAC name | [(6α,11β)-11,17-Dihydroxy-6-methyl-3,20-dioxopregna-1,4-dien-21-yl acetate] |
| Other names |
Fluorometholone 21-acetate
Fluorometholone acetate Fluorometholonacetat FML acetate |
| Pronunciation | /fluːəroʊˌmɛθəˈloʊn əˈsiːteɪt/ |
| Preferred IUPAC name | (6α,11β)-6-Fluoro-11,17-dihydroxy-17-acetylpregna-1,4-diene-3,20-dione |
| Other names |
Fluorometholone 17-acetate
Fluorometanolone acetate Flumetholon acetate AF 1742 NSC 82046 |
| Pronunciation | /fluːˌrɒməˈθəʊloʊn ˈæsɪteɪt/ |
| Identifiers | |
| CAS Number | 82034-46-6 |
| Beilstein Reference | 3922954 |
| ChEBI | CHEBI:31639 |
| ChEMBL | CHEMBL2104061 |
| ChemSpider | 21569064 |
| DrugBank | DB14696 |
| ECHA InfoCard | 100.047.851 |
| EC Number | 211-089-7 |
| Gmelin Reference | 317520 |
| KEGG | C07825 |
| MeSH | D005473 |
| PubChem CID | 11495616 |
| RTECS number | MU4375000 |
| UNII | KUQ6EV8295 |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID5020369 |
| CAS Number | 3397-23-7 |
| 3D model (JSmol) | `/C[C@@H]1[C@H]2C(=O)C=C[C@]2(F)[C@@]3(C)C1CC[C@]4(C)[C@@H]3CCC4(=O)OC(=O)C` |
| Beilstein Reference | 1572226 |
| ChEBI | CHEBI:31636 |
| ChEMBL | CHEMBL1200967 |
| ChemSpider | 21477992 |
| DrugBank | DB14643 |
| ECHA InfoCard | 100.040.797 |
| EC Number | 3.2.1.25 |
| Gmelin Reference | 73442 |
| KEGG | C14414 |
| MeSH | D005473 |
| PubChem CID | 656735 |
| RTECS number | MU4375000 |
| UNII | 24O950N34V |
| UN number | UN3271 |
| CompTox Dashboard (EPA) | DTXSID8017270 |
| Properties | |
| Chemical formula | C24H31FO5 |
| Molar mass | 418.45 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.29 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 2.68 |
| Vapor pressure | 1.7 x 10⁻⁷ mmHg (25°C) |
| Acidity (pKa) | 12.87 |
| Basicity (pKb) | pKb = 12.7 |
| Magnetic susceptibility (χ) | -7.83 × 10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.507 |
| Viscosity | Creamy suspension |
| Dipole moment | 8.62 D |
| Chemical formula | C24H31FO5 |
| Molar mass | 418.43 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.31 g/cm³ |
| Solubility in water | Practically insoluble |
| log P | 2.56 |
| Vapor pressure | 2.58E-11 mmHg at 25°C |
| Acidity (pKa) | 12.25 |
| Basicity (pKb) | 12.45 |
| Magnetic susceptibility (χ) | -7.9e-6 |
| Refractive index (nD) | 1.505 |
| Viscosity | White, odorless crystalline powder |
| Dipole moment | Dipole moment: 4.48 D |
| Pharmacology | |
| ATC code | S01BA07 |
| ATC code | S01BA07 |
| Hazards | |
| Main hazards | May cause eye irritation, skin irritation, and respiratory tract irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07,GHS08 |
| Signal word | Danger |
| Hazard statements | H302 + H332: Harmful if swallowed or if inhaled. |
| Precautionary statements | P264, P280, P305+P351+P338, P304+P340, P312, P337+P313 |
| NFPA 704 (fire diamond) | 1-1-1-0 |
| Autoignition temperature | 460 °C |
| Lethal dose or concentration | LD50 (rat, oral): >3000 mg/kg |
| LD50 (median dose) | LD50 (median dose): Oral (rat): > 3,000 mg/kg |
| NIOSH | MP1595000 |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Fluorometholone Acetate: Not established |
| REL (Recommended) | 0.005 mg/m³ |
| IDLH (Immediate danger) | Not listed |
| Main hazards | Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | Hazard statements: H302, H315, H319, H335 |
| Precautionary statements | P264, P280, P305+P351+P338, P337+P313 |
| Autoignition temperature | 410 °C |
| Lethal dose or concentration | LD50 (oral, rat): > 5,000 mg/kg |
| LD50 (median dose) | 891mg/kg (rat, oral) |
| NIOSH | MP9626000 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 0.005 mg/m³ |
| Related compounds | |
| Related compounds |
Fluorometholone
Corticosteroid esters Prednisolone acetate Dexamethasone acetate |
| Related compounds |
Fluorometholone
Prednisolone acetate Dexamethasone acetate Triamcinolone acetonide Betamethasone acetate |
Providing high-quality chemical products and logistics solutions for global trade partners.
